Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma.

Abstract

BACKGROUND/AIM:

Radioactive iodine-refractory differentiated thyroid carcinoma (RR-DTC) has been treated with multi-kinase inhibitors (MKIs), e.g., sorafenib (SOR) and lenvatinib (LEN). We analyzed the outcomes of RR-DTC patients who underwent SOR or LEN treatment at Kuma Hospital.

PATIENTS AND METHODS:

We enrolled 21 and 18 patients treated with SOR and LEN, respectively.

RESULTS:

The incidence of partial response in the LEN group was significantly higher than that in the SOR group. Serum thyroglobulin significantly decreased from the beginning of treatment to 1 month later in the LEN group (not in the SOR group). The neutrophil-lymphocyte ratio (NLR) was significantly decreased at 1 month later in both groups. An NLR ≥3 at the start of MKI treatment had a prognostic impact.

CONCLUSION:

For RR-DTC, LEN could be more effective than SOR, at least in the short term. The first-line drug should be selected based on other factors (e.g., adverse events, patient background).

• Authors: Yasuhiro Ito, Naoyoshi Onoda, Takumi Kudo, Hiroo Masuoka, Takuya Higashiyama, Minoru Kihara, Akihiro Miya, Akira Miyauchi
• Journal: In vivo (Athens, Greece) (In Vivo) 2021 Mar-Apr Vol. 35 Issue 2 Pg. 1057-1064 ISSN: 1791-7549 [Electronic] Greece
• PMID: 33622902 (Publication Type: Journal Article)
• Copyright: Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Antineoplastic Agents
• Iodine Radioisotopes
• Phenylurea Compounds
• Protein Kinase Inhibitors
• Quinolines
• Sorafenib
• lenvatinib

Topics

• Antineoplastic Agents (therapeutic use)
• Humans
• Iodine Radioisotopes (therapeutic use)
• Phenylurea Compounds (therapeutic use)
• Protein Kinase Inhibitors (therapeutic use)
• Quinolines
• Sorafenib (therapeutic use)
• Thyroid Neoplasms (drug therapy)